Description
Bendamustine is an alkylating medication used for the treatment of patients with CLL (Chronic lymphocytic leukemia), and Indolent B-cell non-Hodgkin’s lymphoma (NHL) that has progressed during or within 6 months of the treatment with rituximab or a rituximab containing regimen.
FAQ's
Is Bendamustin FDA approved drug?
FDA approved this drug in 2008 for the treatment of Chronic lymphocytic leukemia and many more.
What are all the ingredients of medicine along with Bendamustine?
Bendamustine hydrochloride is the active ingredient, and the inactive ingredient is mannitol.
From which class of drug does Bendamustine belong?
Bendamustine specifically belongs to the class of drugs named alkylating agents.
What are commonly reported side effects of bendamustine?
Fever, low blood cell counts, nausea, diarrhea, loss of appetite, cough, and rash